NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

596.75 14.60 (2.51%)

30.61% Fall from 52W High

533.9K NSE+BSE Volume

NSE 02 Sep, 2025 2:37 PM (IST)

26,048.1

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

18 Aug 2022

596.75

2.51%

EARNINGS UPDATE- EMAMI 1QFY23

Buy: Emami Ltd.

Target

Chola Wealth Direct

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

29 Jul 2022

596.75

2.51%

EMAMI LTD

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

Emami Ltd.'s price crossed above 200Day SMA today

Emami Ltd.

19 May 2022

596.75

2.51%

Emami

Buy: Emami Ltd.

Target

Khambatta Securities

Emami Ltd.'s price crossed above 30Day SMA today

Emami Ltd.

29 Mar 2022

596.75

2.51%

Dermicool acquisition: Fairly valued, but not significant

Buy: Emami Ltd.

Target

Motilal Oswal

HMN recently announced the acquisition of the Dermicool brand from Reckitt Benckiser India for INR4.32b. We estimate ~INR1.4b in FY23 sales for Dermicool, with an EBITDA of INR475m, translating in an acquisition cost of ~3x sales and ~9x EBITDA. COVID-led restrictions affected summer season sales in the last two years, impacting overall category growth. Hence, its CY21 sales of INR1.13b are not representative. We believe CY19 sales of INR1.33b are a better representation. The deal will be funded through internal accruals....

Emami Ltd. is trading above all available SMAs

Emami Ltd.

27 Mar 2022

596.75

2.51%

EMAMI LTD

Accumulate: Emami Ltd.

Target

Prabhudas Lilladhar

Near term growth remains a concern given slowdown in rural demand and sharp jump in input costs in past month. While we expect 2/3% price increase in April, poor demand and high inflation will impact profit growth in 1H23 on a high base. We cut EPS estimates of FY23/24 by 5.9/1.3% amidst near term uncertainty. We estimate 11.7% PAT CAGR over FY22-24 and value the stock at 30xDec23 EPS and assign a value of Rs607/share. We believe Rs1.6bn...

Emami Ltd.'s price crossed above 50Day SMA today

Emami Ltd.

13 Feb 2022

596.75

2.51%

Emami

Buy: Emami Ltd.

Khambatta Securities

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Emami Ltd.

03 Feb 2022

596.75

2.51%

EMAMI LTD

Accumulate: Emami Ltd.

Prabhudas Lilladhar

Navratna therapy, Kesh King onion range, Crme 21 products, however it will have any significant impact in a few years only. Although inflation in LLP and Rice bran oil remains high, 3-4% price increase and cost control will enable Emami prevent any significant margin erosion. We estimate 12% PAT CAGR over FY22-24 and value the stock at 30xDec23 EPS and assign a value of Rs624/share. We believe Rs1.6bn buyback (Max...

Emami Ltd.'s price crossed above 100Day SMA today

Emami Ltd.

02 Nov 2021, 12:00AM

596.75

2.51%

EARNINGS UPDATE- EMAMI 2QFY22

Buy: Emami Ltd.

Recommendation Target

Chola Wealth Direct

Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales have grown at a CAGR of 38.5% (FY2010-20)....

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

30 Oct 2021

596.75

2.51%

Margin to come under pressure, but sales traction to continue

Buy: Emami Ltd.

Target

Motilal Oswal

HMN's 2QFY22 sales were in line with our expectations. Domestic sales/ volumes grew 9%/6.2% YoY. With a pickup in the pace of vaccination and diminishing fears of a severe third COVID wave, Healthcare grew only 5% YoY. Nevertheless, the segment was still up 26% on a two-year CAGR basis. On a positive note, revival in mobility led to double-digit growth in discretionary categories BoroPlus, Kesh King, and Male Grooming. While there has been some recent moderation in rural demand, its fundamentals are intact. The outlook for winter demand is positive....

Emami Ltd.'s price crossed above 30Day SMA today

Emami Ltd.

29 Oct 2021

596.75

2.51%

Q2FY22 Result Update - Risk reward favorable on early winter Onset - ACCUMULATE

Accumulate: Emami Ltd.

Recommendation Target

Prabhudas Lilladhar

immunity boosters and higher base of balms in the base year even as Male Boroplus soft showing positive response and will be scaled up. (Rs23mn) led by MTM gain on certain investments in startups. Domestic Grooming, Boroplus, Kesh King and 7 oils in 1 did well. We believe Boroplus,...

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Is Emami Ltd. worth buying?

224 Votes:

Buy 74.55%

Sell 17.41%

Hold 8.04%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf